The phase III PROFILE 1007 study compared crizotinib with chemotherapy as second-line treatment in ALK-rearranged NSCLC patients whose disease had progressed after one prior platinum-based chemotherapy regimen [21]. This evidence concerns the gene ALK and non-small cell lung carcinoma.